Stoke Therapeutics Inc to Present the Analysis of STK-001 for the Treatment of Dravet Syndrome Transcript
Good day and thank you for standing by. Welcome to Stoke Therapeutics Analysis of STK-001 for the Treatment of Dravet Syndrome Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session.
(Operator Instructions)
Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Eric Rojas, Head of Investor Relations. Please go ahead.
Thank you, and good morning. This is Eric Rojas, Head of Investor Relations at Stoke Therapeutics. On today's call, we will discuss new safety and efficacy data from patients treated with STK-001 in the ongoing Phase 1/2a clinical studies, MONARCH and ADMIRAL, and the SWALLOWTAIL Open Label Extension Study in patients with Dravet syndrome.
Our speakers today are Dr. Edward Kaye, Stoke's CEO, Dr. Barry Ticho, Chief Medical Officer, and Dr. Kimberly Parkerson, Head of Neurology
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
